The two companies aim to develop a digital platform containing a variety of data, patient records and successful medical practices, as well as the latest research.
It will facilitate the seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real time monitoring and the latest research outcomes.
The result will be faster, more accurate and more confident decision-making and earlier diagnosis. The platform could also facilitate individualised treatment.
The platform, which Roche describes as an industry first, will initially be used in the fields of oncology and critical care treatment.
“This unique partnership will deliver innovative solutions and insights in clinical decision-making,” commented Roland Diggelmann, CEO of Roche Diagnostics, in a statement.
Kieran Murphy, president and CEO of GE Healthcare, added: “We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry.”